Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase II Evaluation of Docetaxel and Vinorelbine Plus Sargramostim in subjects who
have metastatic melanoma which has advanced beyond the point at which local therapies such as
surgery or radiation therapy would be helpful. Without effective treatment, metastatic
melanoma is usually a severe and fatal disease. Chemotherapy agents or combinations of
chemotherapy agents have produced tumor shrinkage in some patients, which has occasionally
persisted. This research involves treatment with a combination of chemotherapy drugs known to
be active against melanoma alone. The investigational purpose of this study is to determine
if the combination of docetaxel, vinorelbine and sargramostim will produce a response
(complete or partial) in metastasis melanoma. The researchers also wants to find out what
side effects are associated with this combination of drugs.